Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use
the ONA take:
Early discharge following intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce costs and use of intravenous antibiotics, according to a new study published online ahead of print in JAMA Oncology.
Because adults with AML or MDS typically remain hospitalized after induction or salvage chemotherapy, health care costs are driven up by the prolonged inpatient stay. Researchers sought to evaluate whether early discharge and outpatient management would be safe and reduce costs for these patients.
For the study, researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle enrolled 146 patients with AML or MDS. Of those, 107 were discharged early and 29 served as inpatient controls. The early discharge patients were released from the hospital at the completion of chemotherapy and were provided with supportive care in the outpatient setting.
Results showed no significant difference in intensive care unit (ICU) days or transfusions per study day between the two treatment arms. Early discharge patients had more positive blood cultures than the inpatient controls but required fewer intravenous antibiotics. Costs were also lower for the early discharge group than for inpatients but had increased costs per inpatient day when readmitted for complications.
Outpatient Management Following Intensive AML or MDS Chemotherapy
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|